Rekombinanter LAG3 (Relatlimab Biosimilar) Antikörper

Produktnummer ABIN7795123

Dieser Anti-LAG3 (Relatlimab Biosimilar)-Antikörper ist ein Maus-Monoklonal-Antikörper zum Nachweis von LAG3 (Relatlimab Biosimilar) in FACS und in vivo. Geeignet für Human.

Kurzübersicht für Rekombinanter LAG3 (Relatlimab Biosimilar) Antikörper (ABIN7795123)

Target: LAG3 (Relatlimab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser LAG3 (Relatlimab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-LAG3 (Relatlimab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody

Produktmerkmale: What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3-blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer. Relatlimab and the anti-PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti-PD-1 monotherapy.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human LAG-3

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu LAG3 (Relatlimab Biosimilar)

Target: LAG3 (Relatlimab Biosimilar)

Andere Bezeichnung: Relatlimab Biosimilar

Substanzklasse: Biosimilar